Swiss-listed drugmaker ObsEva is abandoning the current program for the company’s drug prospect nolasiban after the agent aimed at boosting pregnancy following in-vitro fertilization (IVF) failed a late-stage study in Europe.

Teva Pharmaceuticals Inc. made more cuts in the United States, this time to real estate holdings. To save money, the company will close its offices in Washington, D.C. and New York City. No jobs were reported to be lost from the cuts.

BioSpace present its NextGen Bio “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.

(Reuters Health) – Women who suffer from a leading cause of infertility may increase their odds of conception if they exercise and lose weight, a U.S. study suggests. Researchers compared pregnancy outcomes for 150 women with polycystic ovary syndrome (PCOS), a condition that occurs when the female body makes higher than normal amounts of testosterone […]

India is set to overtake China and become the world’s most populous country in less than a decade – six years sooner than previously forecast, the United Nations said on Wednesday. Fast-growing Nigeria is on course to outstrip the United States by about 2050 to become the country with the third largest population, the United […]